Lasekan John B, Jacobs Joan, Reisinger Keith S, Montalto Michael B, Frantz Mary P, Blatter Mark M
Abbott Nutrition, Abbott Laboratories, 3300 Stelzer Road, Columbus, OH 43219, USA.
Clin Pediatr (Phila). 2011 Apr;50(4):330-7. doi: 10.1177/0009922810390511.
Lactose, the major carbohydrate in human milk and standard milk-based formulas, provides energy for growth in infants. The use of lactose-free milk protein-based infant formulas has increased in the United States. However, clinical studies of their impact on growth, safety, and gastrointestinal tolerance in infants are limited. Thus, a prospective, blinded, randomized clinical trial was conducted in healthy, normal-term infants fed an experimental lactose-free milk protein-based formula (NoLAC; n = 63) versus a standard commercial lactose-containing milk-based formula (LAC; n = 65) for 112 days. Growth (weight, length, and head circumference) was similar and normal in both groups (weight gain: NoLAC = 31.1 ± 0.9 g/day, LAC = 29.4 ± 0.9 g/day, mean ± SEM; P = .895). Serum biochemistries for both groups were within infants' normal reference ranges. Both groups had comparable tolerance but the NoLAC group had softer stools and lower spit-ups. Thus, the study suggests that absence of lactose in milk-based formula does not adversely affect normal growth in term infants.
乳糖是母乳和标准乳基配方奶粉中的主要碳水化合物,为婴儿生长提供能量。在美国,无乳糖乳蛋白基婴儿配方奶粉的使用有所增加。然而,关于其对婴儿生长、安全性和胃肠道耐受性影响的临床研究有限。因此,对健康足月婴儿进行了一项前瞻性、双盲、随机临床试验,将63名婴儿喂养实验性无乳糖乳蛋白基配方奶粉(NoLAC)与65名婴儿喂养标准商业含乳糖乳基配方奶粉(LAC),为期112天。两组婴儿的生长情况(体重、身长和头围)相似且正常(体重增加:NoLAC = 31.1 ± 0.9克/天,LAC = 29.4 ± 0.9克/天,平均值±标准误;P = 0.895)。两组婴儿的血清生化指标均在正常参考范围内。两组的耐受性相当,但NoLAC组的大便更软,吐奶更少。因此,该研究表明,乳基配方奶粉中不含乳糖不会对足月儿的正常生长产生不利影响。